| Rank |
Pathway / Axis |
Cancer / Tumor Context |
Normal Tissue Context |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
Intrinsic apoptosis (mitochondrial pathway) |
Bax ↑; Bcl-2 ↓; caspases ↑ (reported) |
↔ (less activation) |
G |
Cell death signaling |
Apoptosis induction via mitochondrial membrane disruption is one of the most frequently reported tumor effects. |
| 2 |
NF-κB inflammatory signaling |
NF-κB ↓; cytokines/COX-2 ↓ (reported) |
Inflammation tone ↓ |
R, G |
Anti-inflammatory modulation |
Reduction of inflammatory transcription may contribute to anti-proliferative and anti-invasive effects. |
| 3 |
PI3K / AKT survival pathway |
AKT phosphorylation ↓ (reported; model-dependent) |
↔ |
R, G |
Growth suppression |
Observed in several tumor cell systems; should be presented as context-dependent. |
| 4 |
MAPK signaling (ERK / JNK / p38) |
Stress MAPK modulation (variable direction) |
↔ |
P, R, G |
Signal reprogramming |
JNK activation and ERK suppression have been reported in some models; effects vary by cell type. |
| 5 |
ROS / redox modulation |
ROS ↑ (pro-apoptotic) or ROS ↓ (antioxidant) depending on dose |
Oxidative stress ↓ (protective models) |
P, R, G |
Redox modulation (biphasic) |
Crocetin can behave as antioxidant in normal cells and pro-oxidant in tumor contexts at higher concentrations. |
| 6 |
Cell-cycle arrest |
G0/G1 or G2/M arrest ↑ (reported) |
↔ |
G |
Cytostasis |
Often secondary to survival pathway suppression and stress signaling. |
| 7 |
Angiogenesis signaling (VEGF) |
VEGF ↓; angiogenic signaling ↓ (reported) |
↔ |
G |
Anti-angiogenic support |
Observed in some in vitro and animal tumor models; typically secondary to NF-κB/AKT changes. |
| 8 |
Metabolic reprogramming (glycolysis tone) |
Lactate ↓ (reported; indirect) |
↔ |
R, G |
Warburg modulation (indirect) |
No strong evidence for direct LDH enzyme inhibition; effects likely secondary to survival/redox signaling changes. |
| 9 |
Migration / invasion (MMPs) |
MMP2/MMP9 ↓; invasion ↓ (reported) |
↔ |
G |
Anti-invasive phenotype |
Reported reduction in metastasis markers in certain systems. |
| 10 |
Chemo-sensitization (adjunct potential) |
Therapy sensitivity ↑ (reported in some combinations) |
Normal tissue protection possible |
G |
Adjunct modulation |
May enhance cytotoxic response in some models; data are preclinical. |
| 11 |
Translation constraint |
Clinical anti-cancer efficacy not established |
Generally well tolerated in dietary contexts |
— |
Evidence limitation |
Human oncology data are limited; dosing and bioavailability remain practical considerations. |